iCardiac Technologies, Inc. is a technologically-differentiated cardiac core lab providing the industry’s most sophisticated ICH E14 compliant cardiac safety assessment methodologies for Phase I through Phase IV studies, supported by expert scientific consultation, end-to-end project management, worldwide site and equipment logistics, 24/7 customer support and regulatory data submission.
iCardiac’s analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement, including our Highly Automated QTsm, which has been extensively validated by pharmaceutical companies and regulators as equivalent to manual evaluation of QT prolongation, and has supported cardiac safety studies more frequently than any other automated QT method.
In addition, iCardiac provides Dynamic QTbtbsm, a suite of advanced ECG-based cardiac safety markers that have been accepted and used as secondary end-points in regulatory approvals, and deliver a more accurate assessment of the cardiac safety profile of drugs in development.
iCardiac’s COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies.
Chief tech officer at iCardiac Technologies will lead effort Feeling the Beat
Sasha Latypova and Mikael Totterman at iCardiac look at de-risking drug candidates in early clinical development Drug Safety Executive Council – De-Risking Drug Candidates in Early Clinical Development Intelligent ECG: Three years after the E14 guidance, Alexandra Latypova at iCardiac Technologies, Inc investigates new cardiac safety assessment challenges and potential solutions in European Pharmaceutical Contractor Spring 2009 Issue Drug Discovery & Development: What Lies Ahead? Drug Research Predictions - iCardiac Technologies
by Drug Discovery & Development University of Rochester Medical Center, FDA to Collaborate on National Data Repository for Heart Research In a Heartbeat as seen in Samedan LTD Spring 2008 Screen Door is Wide Open as seen in R&D Directions April 2008 Universities and the local economy True to Heart: ECG biomarkers are discussed in April 2008 online edition of Drug Discovery & Development Strong pulse at iCardiac in Brighton Integrated approach to TQT CenterWatch Profile on Cardiac Safety Network News 13 WHAM: "UR Spins Off Support for High Tech Business" Engineering K12 Center: "Ending Pharmaceutical Heartbreak" Rochester Medicine: “Leadership in Technology Commercialization” Health Business Blog: "Interview with Chairman and CEO of iCardiac, Mike Totterman" Rnews: "Entrepreneurs Make Their Pitch" Start-Up Magazine (In Vivo Publication): "iCardiac Technologies Inc. - A Better Rhythm for Drug Development" R&D Directions: "A Cardiac Pact"
April 29th, 2009. Silver Spring, MD. QT and Arrhythmia Issues in Drug Development, April 6-8, 2008 at the Hyatt Regency Bethesda in Bethesda, MD. October 15-31, 2007, hosted over the Internet by the International Society for Holter and Noninvasive Electrocardiology (ISHNE). October 2nd, 2007 Durham, North Carolina October 24th and 25th, 2007 Copthorne Tara Hotel, London December 3-4, 2007, Dorint Praha Don Giovanni Hotel, Prague, Czech Republic
